NCT04217993View on ClinicalTrials.gov

Jaktinib for the Treatment of Ruxolitinib Intolerance of Myelofibrosis

PHASE2CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

January 7, 2020

Primary Completion Date

August 3, 2022

Study Completion Date

August 3, 2022

Conditions
Primary Myelofibrosis (PMF)Post-polycythemia Vera Myelofibrosis(Post-PV MF)Post-essential Thrombocythemia Myelofibrosis(Post-ET MF)
Interventions
DRUG

Jaktinib hydrochloride tablets

Jaktinib hydrochloride tablets 100mg twice dose group，Jaktinib hydrochloride tablets 150mg qd dose group, Jaktinib hydrochloride tablets 200mg qd dose group and Jaktinib hydrochloride tablets 100mg qd dose group

Trial Locations (1)

310003

The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou

All Listed Sponsors
lead

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

INDUSTRY

NCT04217993 - Jaktinib for the Treatment of Ruxolitinib Intolerance of Myelofibrosis | Biotech Hunter | Biotech Hunter